Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.11.24	Xencor Reports Third Quarter 2024 Financial Results (Businesswire)
04.11.24	Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease (Businesswire)
10.10.24	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Businesswire)
04.10.24	Xencor Announces Upcoming Change to Board of Directors (Businesswire)
12.09.24	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
11.09.24	Xencor Prices Public Offering Of 6.64 Mln Shares At $18/shr (RTTNews)
11.09.24	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Businesswire)
10.09.24	Xencor Announces Proposed Public Offering of Common Stock (Businesswire)
09.09.24	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Businesswire)
06.09.24	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Businesswire)
05.08.24	Xencor Reports Second Quarter 2024 Financial Results (Businesswire)
13.06.24	Xencor To Regain Global Rights To Bispecific T-Cell Engager Plamotamab (RTTNews)
13.06.24	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Businesswire)
09.05.24	Xencor Reports First Quarter 2024 Financial Results (Businesswire)
09.04.24	Xencor Appoints Bart Cornelissen As CFO (RTTNews)
09.04.24	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Businesswire)
28.02.24	Xencor to Present at Upcoming Investor Conferences (Businesswire)
27.02.24	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
20.02.24	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update (Businesswire)
03.01.24	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Businesswire)
02.01.24	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy (Businesswire)
21.11.23	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference (Businesswire)
07.11.23	Xencor Reports Third Quarter 2023 Financial Results (Businesswire)
07.11.23	Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million (Businesswire)
03.11.23	Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting (Businesswire)
31.10.23	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 (Businesswire)
26.10.23	Xencor CFO John Kuch To Retire In 2024 (RTTNews)
26.10.23	Xencor Announces Planned Retirement of Chief Financial Officer John Kuch (Businesswire)
27.09.23	Xencor to Present Multiple Posters at the SITC Annual Meeting (Businesswire)
19.09.23	Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors (Businesswire)
03.08.23	Xencor Reports Second Quarter 2023 Financial Results (Businesswire)
27.07.23	Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023 (Businesswire)
31.05.23	Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress (Businesswire)
08.05.23	Xencor Reports First Quarter 2023 Financial Results (Businesswire)
01.05.23	Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023 (Businesswire)
26.04.23	Xencor Appoints Nancy Valente, M.D., as Chief Development Officer (Businesswire)
17.04.23	Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023 (Businesswire)
14.03.23	Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023 (Businesswire)
23.02.23	Xencor Reports Fourth Quarter and Full Year 2022 Financial Results (Businesswire)
16.02.23	Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (Businesswire)
07.02.23	Xencor to Present at the SVB Securities Global Biopharma Conference (Businesswire)
09.01.23	Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates (Businesswire)
05.01.23	Caris, Xencor Expand Collaboration To Develop XmAb Antibodies (RTTNews)
05.01.23	Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates (PR Newswire)
04.01.23	Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
12.12.22	Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting (Businesswire)
10.11.22	Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting (Businesswire)
07.11.22	Xencor Reports Third Quarter 2022 Financial Results (Businesswire)
07.11.22	Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study (Businesswire)
03.11.22	Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten